New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Trinity Biotech’s CGM+ is supported by analysis of over 5,000 hours of clinical wear data showing it can distinguish nocturnal compression-related false lows from true blood glucose lows. The validation improves confidence in the product’s accuracy in a key at-night use case, which may be viewed positively by investors but is not yet a clear financial catalyst.

Analysis

Trinity Biotech’s CGM+ is supported by analysis of over 5,000 hours of clinical wear data showing it can distinguish nocturnal compression-related false lows from true blood glucose lows. The validation improves confidence in the product’s accuracy in a key at-night use case, which may be viewed positively by investors but is not yet a clear financial catalyst.